Articles from Nirrin Technologies

Nirrin Technologies, a developer of analytical tools designed to transform bioprocessing workflows, today announced the appointment of S.T. Japan as its exclusive distribution partner for the TALOS™ protein quantitation system in Japan.

Nirrin Technologies, a developer of analytical tools designed to transform bioprocess workflows, today announced the commercial launch of TALOS™, a direct protein quantitation system built on the company’s proprietary High-Precision Tunable Laser Spectroscopy (HPTLS™) technology. TALOS™ simplifies protein quantitation across biopharmaceutical workflows by replacing traditional variable pathlength UV workflows with fixed-path near-infrared (NIR) measurement of the peptide backbone. Protein quantitation is possible from 0.1 to 250 mg/mL, in seconds from a 15 µL sample, without dilution, moving optical systems, molecule-specific calibration, or manual pathlength adjustment.

Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, today announced the issuance of a new patent (US 12,222,279 B2) for its advanced flow-cell technology, reinforcing the company’s commitment to driving innovation in bioprocess analytics. This milestone expands Nirrin’s capabilities in real-time process monitoring, offering greater precision, flexibility, and efficiency to bioprocessing workflows. By integrating active temperature regulation, precise optical path control, and a versatile form factor, this newly patented innovation elevates real-time bioprocess monitoring. It enables more consistent, high-quality data to support better decision-making and process optimization.

Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, today announced the founding of its Scientific Advisory Board (SAB), with key experts in diverse fields across biomanufacturing and advanced therapeutic development joining as inaugural members.

Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, today announced a joint partnership with Boston BioProducts, a cGMP manufacturer of custom buffers for research, diagnostics, drug development, and bioprocessing applications. The partnership between these two Boston-based companies intends to establish a new standard of QC excellence in buffer manufacturing with Nirrin’s Atlas™ system as a central analytical testing tool.

Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, has been awarded a $2 million Small Business Innovation Research (SBIR) Direct Phase II Grant from the National Institutes of Health (NIH). This grant will fund further development of Nirrin’s proprietary high-precision tunable laser spectroscopy™ (HPTLS) platform for biomanufacturing applications.

Nirrin Technologies, a developer of analytical tools poised to transform bioprocess analysis, today announced the launch of their Atlas™ system for at-line excipient and product titer quantitation in downstream bioprocessing applications.

Nirrin Technologies, a company developing analytical systems to transform analysis for bioprocessing operations, announced that Greg Crescenzi has joined the company as its Chief Executive Officer.

Nirrin Technologies, a company developing analytical systems to transform analysis for downstream bioprocessing operations, showcased three enabling at-line/in-line applications in poster presentations for buffer verification, UF/DF endpoint detection and dilution-free protein quantitation at the BioProcess International conference last week in Boston.